AbbVie on Monday jumped into the hot weight-loss space, looking to gain ground on its Big Pharma peers, with a licensing deal ...
Novo Nordisk launched "My Ozempic® Era" today, a national campaign which spotlights the longstanding Ozempic® patient ...
Consumers who use telehealth or medical spas to get less expensive, compounded weight loss drugs will need to get their ...
Newser on MSN1d
FDA Change on Ozempic to Shake Up the MarketThe shortage of Ozempic and Wegovy has been declared over by the Food and Drug Administration, a change that suggests higher ...
Nearly one-third of adult employees would change jobs in order to gain coverage. As the demand for GLP-1 weight loss ...
Irish Examiner on MSN3d
On the rebound: What are the long-term risks of Ozempic?Ahead of World Obesity Day, we examine the impact of the game-changing drugs that control appetite. Increasingly being taken ...
Outsourcing Facilities Association and North American Custom Laboratories allege the FDA removed semaglutide from its ...
New diabetes medications are pressuring Medicare Part D financially as they drive up prescription drug costs amid rising ...
Drug compounders aren’t ready to give up their ability to produce off-brand versions of Novo Nordisk’s weight-loss drug ...
Despite the continued success of GLP-1 drugs Ozempic and Wegovy, Novo Nordisk CEO Lars Fruergaard Jørgensen took a slight pay cut in 2024. He received 57.1 million Danish kroner (DKK) – $8 million – ...
A lawsuit challenges the FDA's decision to remove semaglutide from the shortage list, alleging it was arbitrary and harms ...
We recently published an article titled Two of 10 Worst-Performing Stocks Fall to All-Time Lows on Tuesday. In this article, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback